285 related articles for article (PubMed ID: 1697623)
1. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
Awouters F; Niemegeers CJ; Megens AA; Janssen PA
J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623
[TBL] [Abstract][Full Text] [Related]
2. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Janssen PA; Awouters FH
Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
5. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
Leysen JE; Janssen PM; Megens AA; Schotte A
J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
[TBL] [Abstract][Full Text] [Related]
6. [Serotonin antagonism involved in the antipsychotic effect. Confirmation with ritanserine and risperidone].
Niemegeers CJ; Awouters F; Janssen PA
Encephale; 1990; 16(2):147-51. PubMed ID: 1693560
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
[TBL] [Abstract][Full Text] [Related]
8. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol.
Megens AA; Niemegeers CJ; Awouters FH
J Pharmacol Exp Ther; 1992 Jan; 260(1):160-7. PubMed ID: 1370539
[TBL] [Abstract][Full Text] [Related]
9. Biochemical profile of risperidone, a new antipsychotic.
Leysen JE; Gommeren W; Eens A; de Chaffoy de Courcelles D; Stoof JC; Janssen PA
J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616
[TBL] [Abstract][Full Text] [Related]
10. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity.
Szczepanik AM; Brougham LR; Roehr JE; Conway PG; Ellis DB; Wilmot CA
J Pharmacol Exp Ther; 1996 Aug; 278(2):913-20. PubMed ID: 8768747
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
13. Dopaminergic and serotonergic mechanisms of thermoregulation: mediation of thermal effects of apomorphine and dopamine.
Yamawaki S; Lai H; Horita A
J Pharmacol Exp Ther; 1983 Nov; 227(2):383-8. PubMed ID: 6631720
[TBL] [Abstract][Full Text] [Related]
14. Partial inhibition of reverse tolerance by a high dose of ritanserin or low dose of haloperidol in methamphetamine-sensitized rat.
Tanaka T; Ishigooka J; Watanabe S; Nagata E; Miura S
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Feb; 18(1):1-7. PubMed ID: 9592805
[TBL] [Abstract][Full Text] [Related]
15. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.
Bowden CR; Voina SJ; Woestenborghs R; De Coster R; Heykants J
J Pharmacol Exp Ther; 1992 Aug; 262(2):699-706. PubMed ID: 1380082
[TBL] [Abstract][Full Text] [Related]
16. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
[TBL] [Abstract][Full Text] [Related]
17. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
Schotte A; Janssen PF; Megens AA; Leysen JE
Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
[TBL] [Abstract][Full Text] [Related]
18. Serotonergic involvement in haloperidol-induced catalepsy.
Neal-Beliveau BS; Joyce JN; Lucki I
J Pharmacol Exp Ther; 1993 Apr; 265(1):207-17. PubMed ID: 8386235
[TBL] [Abstract][Full Text] [Related]
19. Survey on the pharmacodynamics of the new antipsychotic risperidone.
Megens AA; Awouters FH; Schotte A; Meert TF; Dugovic C; Niemegeers CJ; Leysen JE
Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
[TBL] [Abstract][Full Text] [Related]
20. Central antiserotonergic and antidopaminergic action of pirenperone, a putative 5-HT2 receptor antagonist.
Pawłowski L; Siwanowicz J; Bigajska K; Przegaliński E
Pol J Pharmacol Pharm; 1985; 37(2):179-96. PubMed ID: 4048012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
